PDEs as drug targets
Phosphodiesterases make good drug targets because they bind small ligands and share similar catalytic mechanisms, while displaying unique architectures around their active sites. This allows for the development of selective inhibitors.
PDE4NPD and the EU
The PDE4NPD Project is one of four neglected parasitic disease (NPD) projects funded under the auspices of the European Commission’s FP7 HEALTH programme.
PDE4NPD at EFMC International Symposium on Medicinal Chemistry
Several members of the PDE4NPD consortium will be presenting at the XXIV EFMC International Symposium on Medicinal Chemistry, in Manchester, UK, from August 28 - September 1. Would you like to learn more about the PDE4NPD project? Visit our posters!